Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2016: TAF/FTC Maintains Viral Suppression as Well as TDF with Less Bone and Kidney Toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched from similar regimens containing the older tenofovir disoproxil fumarate (TDF), according to a report presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)this week in Boston. The study also showed improvement in kidney function biomarkers and bone density gains in the group taking TAF/FTC.

alt

Read more:

CROI 2016: Long-Acting Injectable Cabotegravir + Rilpivirine Works Well as HIV Maintenance Therapy

A combination of 2 long-acting injectable antiretrovirals, cabotegravir and rilpivirine, given once every 4 or 8 weeks, maintained viral suppression as well as standard oral antiretroviral therapy (ART) and appeared safe and well-tolerated, according to results from the LATTE 2 trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) taking place this week in Boston.

alt

Read more:

HIV Medicine Association Cautions Against Excessive HIV-Related Testing

The HIV Medicine Association (HIVMA) has released new recommendations calling on HIV care providers to avoid routine use of unnecessary monitoring tests, including frequent CD4 T-cell counts and viral load tests for people on stable suppressive antiretroviral therapy.

alt

Read more:

CROI 2016: Starting HIV Treatment at First Clinic Visit Improves Outcomes in African Study

A program to accelerate the process of HIV diagnosis, preparation, and starting antiretroviral therapy (ART) in South Africa led to a higher proportion of people initiating treatment and better health outcomes, according to results from the RapIT trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)taking place this week in Boston.

alt

Read more:

Tenofovir Resistance May Develop in More than Half of Patients Failing Treatment

More than half of people who experienced failure of a tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to tenofovir, a meta-analysis of drug resistance studies published in the January 28 online edition of Lancet Infectious Diseases has shown. The study found that the prevalence of tenofovir resistance after first-line treatment failure ranged from 20% in Western Europe and North America to 56%-60% in sub-Saharan Africa.

alt

Read more:

Conference on Retroviruses and Opportunistic Infections Starts Next Week in Boston

The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) will take place next week, February 22-25, at the Hynes Convention Center in Boston. Starting Monday, HIVandHepatitis.com and our partners at Aidsmap will provide on-site coverage of HIV pre-exposure prophylaxis (PrEP), new HIV treatments, and more.

alt

Read more:

Long-term Tenofovir Use Associated with Increased Risk of Serious Liver Disease

Long-term therapy with the antiretroviral drug tenofovir (Viread, also in several coformulations including Truvada and Atripla) increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published in the January 18 online edition of AIDS. Researchers found that 5-year cumulative use of the drug increased the relative risk of serious liver disease by 46%.

alt

Read more: